Actinomycin D (Dactinomycin)

Catalog No.S8964 Batch:S896402

Print

Technical Data

Formula

C62H86N12O16
Molecular Weight 1255.42 CAS No. 50-76-0
Solubility (25°C)* In vitro DMSO 100 mg/mL (79.65 mM)
Water Insoluble
Ethanol Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O
3.75mg/ml Taking the 1 mL working solution as an example, add 50 μL 75 mg/ml clarified DMSO stock solution to 400 μL PEG300, mix evenly to clarify it; add 50 μL Tween80 to the above system, mix evenly to clarify it; then continue to add 500 μL ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Actinomycin D (Dactinomycin, Act D, RASP-101) is a significant polypeptide antibiotic isolated from soil bacteria of the genus Streptomyces. Actinomycin D (Dactinomycin) inhibits DNA repair and rests the cell cycle at G1 phase with IC50 of 0.42 μM and 0.4 nM, respectively. Actinomycin D is an autophagy activator, induces p53-independent cell death and prolongs survival in high-risk chronic lymphocytic leukemia.This product is a hazardous chemical (acute toxicity/flammable/skin corrosive). Please use it while wearing a protective face mask, gloves, and clothing.
Targets
autophagy [3] cell cycle [1]
(Cell-based assay)		 DNA repair [2]
(Cell-free assay)
0.4 nM 0.42 μM
In vitro

Actinomycin D markedly reduces the SMC proliferation via the inhibition of BrdU incorporation at 80 nM. This is further supported by the G1-phase arrest using a flowcytometric analysis. The protein expression levels of proliferating cell nuclear antigen (PCNA), focal adhesion kinase (FAK), and Raf are all suppressed by actinomycin D. Extracellular signalregulated kinases (Erk) involved in cell-cycle arrest are found to be increased by actinomycin D.[1]
In vivo

Actinomycin D targets survival proteins TOSO, BCL2 and MCL1 and is active in two different mouse models that are characterized by either unmutated B-cell receptor or inactive p53 function, both of which are known negative prognostic factors in CLL.[3]

Protocol (from reference)

Cell Assay:

[1]
  • Cell lines

    A10 cells (Vascular SMC)

  • Concentrations

    80 nM, 800 nM, 8 μM

  • Incubation Time

    18-24 h

  • Method

    Cultured SMC are starved for 24 h followed by incubation with various doses of actinomycin D at 37℃. Drug treatment is carried out for 18-24 h. Since actinomycin D is dissolved in 0.1% DMSO, a vehicle control containing DMSO is also included.
Animal Study:

[3]
  • Animal Models

    C57BL/6 wild-type mice engrafted with tumor cells from Em-TCL-1 transgenic mice

  • Dosages

    0.06 mg/kg

  • Administration

    IP

Selleck's Actinomycin D (Dactinomycin) has been cited by 75 publications

RNA m6A modification regulates L1 retrotransposons in human spermatogonial stem cell differentiation in vitro and in vivo [ Cell Mol Life Sci, 2024, 81(1):92] PubMed: 38363375
Exosomal circRHCG promotes breast cancer metastasis via facilitating M2 polarization through TFEB ubiquitination and degradation [ NPJ Precis Oncol, 2024, 8(1):22] PubMed: 38287113
O-GlcNAcylation of YTHDF2 promotes HBV-related hepatocellular carcinoma progression in an N6-methyladenosine-dependent manner [ Signal Transduct Target Ther, 2023, 8(1):63] PubMed: 36765030
Mevalonate improves anti-PD-1/PD-L1 efficacy by stabilizing CD274 mRNA [ Acta Pharm Sin B, 2023, 13(6):2585-2600] PubMed: 37425040
A patient-derived organoid-based study identified an ASO targeting SNORD14E for endometrial cancer through reducing aberrant FOXM1 Expression and β-catenin nuclear accumulation [ J Exp Clin Cancer Res, 2023, 42(1):230] PubMed: 37667311
A patient-derived organoid-based study identified an ASO targeting SNORD14E for endometrial cancer through reducing aberrant FOXM1 Expression and β-catenin nuclear accumulation [ J Exp Clin Cancer Res, 2023, 42(1):230] PubMed: 37667311
E3 ligase HECTD3 promotes RNA virus replication and virus-induced inflammation via K33-linked polyubiquitination of PKR [ Cell Death Dis, 2023, 14(7):396] PubMed: 37402711
METTL14-dependent maturation of pri-miR-17 regulates mitochondrial homeostasis and induces chemoresistance in colorectal cancer [ Cell Death Dis, 2023, 14(2):148] PubMed: 36810285
circPTPN12 promotes the progression and sunitinib resistance of renal cancer via hnRNPM/IL-6/STAT3 pathway [ Cell Death Dis, 2023, 14(3):232] PubMed: 37002206
NRP1 promotes prostate cancer progression via modulating EGFR-dependent AKT pathway activation [ Cell Death Dis, 2023, 14(2):159] PubMed: 36841806

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.